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Abstract
Height is a heritable and highly heterogeneous trait. Short stature affects 3% of the population and in most cases is genetic in origin.
After excluding known causes, 67% of affected individuals remain without diagnosis. To identify novel candidate genes for short
stature, we performed exome sequencing in 254 unrelated families with short stature of unknown cause and identiﬁed variants in 63
candidate genes in 92 (36%) independent families. Based on systematic characterization of variants and functional analysis
including expression in chondrocytes, we classiﬁed 13 genes as strong candidates. Whereas variants in at least two families were
detected for all 13 candidates, two genes had variants in 6 (UBR4) and 8 (LAMA5) families, respectively. To facilitate their
characterization, we established a clustered network of 1025 known growth and short stature genes, which yielded 29 signiﬁcantly
enriched clusters, including skeletal system development, appendage development, metabolic processes, and ciliopathy. Eleven of
the candidate genes mapped to 21 of these clusters, including CPZ, EDEM3, FBRS, IFT81, KCND1, PLXNA3, RASA3, SLC7A8,
UBR4, USP45, and ZFHX3. Fifty additional growth-related candidates we identiﬁed await conﬁrmation in other affected families.
Our study identiﬁes Mendelian forms of growth retardation as an important component of idiopathic short stature.
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Introduction
Human height is a heritable and highly heterogeneous trait
[1]. Efforts to understand the genetic basis of growth have
employed genome-wide association studies (GWAS) to
systematically assess the effect on human height variation
of common variants with a minor allele frequency > 5% [2].
697 variants, mainly located in 423 noncoding loci, have
been implicated in height variance in the population [2, 3].
Subsequent studies on rare variants, both at the nucleotide
and genomic levels, further expanded the number of asso-
ciated loci [3, 4]. So far, rare and common height-associated
variants together explain about 27.4% of height heritability
[3]. In addition, it is known from Mendelian forms of
growth retardation that rare, large effect-size variants can
have extremely large effects on growth development [3].
Short stature, deﬁned auxologically as a height two
standard deviations below the mean height in the popula-
tion, affects about 3% of individuals and is a common
medical concern. In a recent study combining systematic
phenotyping and exome-based sequencing, we were able to
identify a genetic cause in up to 33% of individuals with
idiopathic short stature (ISS) [5]. Consequently, 67% of the
affected individuals remained undiagnosed. Most forms of
short stature have been attributed to Mendelian causes,
highlighting defects in a diverse range of functional path-
ways [6, 7]. The most common monogenic causes include
defects of the SHOX gene (2.4%) [8], heterozygous variants
in ACAN (1.4%) [9] and many genes for rare syndromic
forms as well as skeletal dysplasias [8, 10–12]. At least 477
genes have been found to affect human growth [13], but as
yet there are no reliable estimates of the number of growth-
associated genes. For most of these genes, though, no
association with short stature has been found in humans.
Affected individuals and their families would thus beneﬁt
from the identiﬁcation of further genes associated with
growth retardation. In this study in 254 unrelated indivi-
duals with ISS and their families, we used exome sequen-
cing to identify and characterize novel candidate genes
based on evolutionarily conserved networks.
Materials and methods
Individuals
The study was approved by the ethics committee of the
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
565 individuals and their families were referred by medical
specialists for evaluation of growth retardation after endo-
crine defects of the growth hormone pathway and other
organic causes of growth retardation were excluded. After
previous targeted testing including array analysis in some
and exome sequencing failed to identify a known cause, we
further assessed the exomes of 254 well-characterized
families with at least 1 offspring whose growth standard
deviation score (SDS) was ≥2 below the mean population
height and/or the estimated family (est. height in Table 1)
for potential candidate genes (Table 1 and Supplementary
Table 2). Participants’ mean age (±standard deviation) was
9.2 ± 0.43 years, and 155/254 (61%) participants were
female. Most index individuals (53%) presented with a
height between 3 and 2 SDS below the mean, and 32% were
born small for gestational age (Supplementary Figure 1). In
68/254 (27%) participants, additional features such as
Table 1 Clinical characteristics of 254 individuals with idiopathic
short stature after exclusion of known causes
Characteristic No. (%)
Age group
<4 yrs 43 (17)
>4 yrs 211 (83)
Small for gestational age 81 (32)
Short stature [SDS]a
−2 to −3 135 (53)
−3 to −4 55 (22)
−4 to −5 12 (5)
<−5 4 (2)
Below est. heightb 48 (19)
Short stature type
Isolated 186 (73)
Syndromic 68 (27)
Head circumference [SDS]
>−2 153 (60)
−2 to −3 38 (15)
−3 to −5 32 (13)
<−5 3 (1)
Not available 28 (11)
IQ
Normal 203 (80)
70–85 51 (20)
Sex
Female 155 (61)
Male 99 (39)
Bone age
Accelerated 11 (4)
Normal 21 (8)
Delayed 66 (26)
Not available 156 (61)
aAll 254 affected individuals presented with a height below the est.
ﬁnal adult height (est. height)
bAffected individuals with a height above −2 SDS, but below the est.
height
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microcephaly, syndactyly, nail dysplasia or any nonspeciﬁc
facial gestalt resulted in a diagnosis of syndromic short
stature.
Exome sequencing and variant assessment
We performed whole-exome sequencing in 185 affected
individuals and both of their respective parents (trio ana-
lysis) and in 69 affected individuals (affected-only analysis)
after enrichment by SureSelect targeted capturing on HiSeq
2500 (94.3%) or SOLiD 5500xl (5.7%). Exomes were
analyzed by semiautomatic selection and data quality
inspection of variants, followed by the interpretation in
relation to the reported phenotypic spectrum (Supplemen-
tary Figures 2 and 3). Variants and familial segregation
were conﬁrmed by Sanger sequencing.
All 185 trios were analyzed for variants with de novo,
compound heterozygous, homozygous, and X-linked
recessive inheritance. We classiﬁed variants according to
their population frequency and potential effect on gene
function (Supplementary methods, Fig. 1c and Supple-
mentary Tables 1–3). Population data from gnomAD was
considered as most likely appropriate controls. After
excluding benign and likely benign variants, we evaluated
affected genes for their relevance to growth phenotypes. For
this gene-level assessment, we included information from
association studies, copy number variants, gene ontology
(GO) terms, protein–protein interaction data, suitable mouse
and zebraﬁsh models, and a previous exome study [14]
(Fig. 1d and Supplementary Table 4). Additional data on
expression in chondrocytes was obtained by RNA sequen-
cing (RNASeq) of cartilage tissue for all genes studied
(Fig. 1d, Supplementary Methods and Figure 4). The
combined results of the variant-level and gene-level
assessments were then used to identify genes, which were
further investigated with respect to the observed mode
of inheritance in the 69 affected-only exomes (Fig. 1e,
Supplementary Methods, Supplementary Figure 2 and
Supplementary Table 5). Genes were ﬁnally classiﬁed as
high-conﬁdence and medium-conﬁdence candidates based
on the number of affected individuals and the combined
variant-level and gene-level scores (Supplementary Table 6
and Supplementary Methods). Variants were uploaded to
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/, Submis-
sion ID SUB5032330).
Functional clustering analysis
Functional enrichment analysis was performed using the
Database for Annotation, Visualization, and Integrated
Discovery, which comprises 1025 Genes using the key-
words “growth delay” from the Human Phenotype Ontol-
ogy (HPO) database and “short stature” from Online
Mendelian Inheritance in Man (OMIM) and MedGen
(Supplementary methods). Proteins were submitted to
DAVID using human gene Ensembl identiﬁers. Sig-
niﬁcantly overrepresented annotation terms were retrieved
with the options GOTERM_MF_ALL, GOTERM_
CC_ALL, GOTERM_BP_ALL, KEGG_PATHWAY,
UP_KEYWORDS, and OMIM_DISEASE. A false dis-
covery rate (FDR) of 0.05 by the Benjamini and Hochberg
approach was used to determine signiﬁcant enrichment using
all human gene Ensembl identiﬁers in the BioMart database
as the background (Supplementary methods). Functional
Annotation Clustering was performed using the DAVID
functional annotation clustering tool with the following
parameters: overlap= 5, initialSeed= 5, ﬁnalSeed= 5,
linkage= 0.5, kappa= 20. This tool implements a fuzzy
clustering algorithm to cluster functional annotation terms
based on the degree of the overlap between associated genes.
Raw p-values were used to compute the initial clusters.
Annotation terms with an FDR > 0.05 were subsequently
pruned. Given a list of candidate genes and an annotation
term, we calculated (i) the odds of a human gene (Ensembl
gene identiﬁer) in the list being associated with the anno-
tation term; and (ii) the odds of a human gene (Ensembl
gene identiﬁer) not in the list being associated with the term.
The odds ratio was calculated by dividing the odds from
(i) by the odds from (ii) using the ﬁsher.test () function
implemented in the R environment for statistical computing.
Results were presented as a treemap based on the functional
annotation clustering using R’s treemap package.
Protein structure analysis
For all variants of unknown signiﬁcance in high-conﬁdence
candidate genes and for missense variants in RASA3, we
performed in silico structural analyses and reclassiﬁed
variants based on predicted functional consequences
(Fig. 1f and Supplementary Figure 8). Models for all wild-
type protein domains were either obtained from Modbase
[15] or modelled using HHpred [16] and Modeller [17]. The
variant amino acid was exchanged using Swiss-Model [18]
and visualized with RasMol [19]. Detailed information on
individual modelling is provided in the Methods section in
the supplementary information.
Results
Identiﬁcation of novel candidate genes for ISS
Characterization of involved variants and genes and con-
sideration of independent affected individuals carrying
these variants revealed 63 candidate genes in 92 (36%) of
the 254 affected individuals included in the analysis. We
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classiﬁed 13 genes as high-conﬁdence genes and the
remaining 50 genes as medium-conﬁdence candidates
(Tables 2 and 4, Supplementary Tables 7 and 11, and
Supplementary Figures 6–18). The mode of inheritance was
mainly autosomal dominant (71%), followed by X-linked
recessive (17%), and autosomal recessive (11%). The most
Fig. 1 Enrichment analysis and candidate gene characterization.
a Functional clustering of 1,025 known growth and short stature genes
(b) into 29 biological clusters for growth. c Variant level assessment.
Number of variants affecting function or likely affecting function and
variants of unknown signiﬁcance identiﬁed (Supplementary Tables 1,
2). d Categories of gene level assessment. Numbers represent the
genes to which each category applies (see Supplementary Table 4).
Numbers in brackets represent the genes among all selected known
growth and short-stature genes. e The results of the variant and gene
level evaluation were merged to a combined score (Shown is the
highest score for each gene, Supplementary Table 5). f Based on
structure analysis of variants of unknown signiﬁcance (VUS), 5
variants in 4 of the high-conﬁdence candidate genes were reclassiﬁed
to likely pathogenic. Model of the RASA3 C2-domain showing the
site of the Asp82Glu and Val85Ala variants. Both residues are located
in a pocket of the C2 domains that contains two Ca2+ ions (Ca). Asp82
forms interactions with both Ca2+ ions (green dotted lines), whereas
the longer glutamate side chain of the Asp82Glu variant can only
interact with one of the Ca2+ ions, probably leading to a loss of the
second Ca2+ ion from the binding pocket. Val85 (blue) is located on
the lateral wall of this pocket, and the shorter alanine side chain in the
Val85Ala variant affects the width of the pocket. g Distribution of the
63 high- and medium-conﬁdence candidate genes in the growth-
associated clusters
1064 N. N. Hauer et al.
Ta
bl
e
2
C
at
eg
or
ie
s,
fu
nc
tio
n
an
d
ph
en
ot
yp
e
ov
er
vi
ew
of
id
en
tiﬁ
ed
hi
gh
-c
on
ﬁ
de
nc
e
ca
nd
id
at
e
ge
ne
s
G
en
e
N
o.
pa
ts
.
V
ar
ia
nt
le
ve
l
cl
as
si
ﬁ
ca
tio
ne
G
en
e
le
ve
l
cl
as
si
ﬁ
ca
tio
n
[N
o.
of
ca
t.]
c
C
om
bi
ne
d
sc
or
e
[1
–
4]
M
ai
n
pa
th
w
ay
d
P
he
no
ty
pe
V
IV
II
I
H
ei
gt
h
[S
D
S
±
s]
O
F
C
[S
D
S
±
s]
S
yn
dr
om
ic
C
om
m
on
fe
at
ur
es
(n
o.
of
in
di
vi
du
al
s)
C
P
Z
3a
3
1
3
−
3.
6
±
1.
4
−
2.
3
±
1
0/
3
S
ho
rt
ne
ck
(2
/3
),
hy
pe
rt
el
or
is
m
(2
/3
),
lo
w
se
t
ea
rs
(3
/3
),
w
id
e
in
te
rm
am
m
ill
ar
y
di
st
an
ce
(2
/3
)
E
D
E
M
3
2
2
3
3
P
ro
te
in
pr
oc
es
si
ng
−
2
±
0.
1
−
1.
7
±
0.
7
0/
3
H
ig
h
ar
ch
ed
ey
e
br
ow
s
(2
/2
),
th
in
up
pe
r
lip
(2
/2
)
F
B
R
S
3a
2
1
3
3
−
2.
2
±
−
0.
2
−
2
±
0.
4
0/
3
T
hi
n
ha
ir
(2
/3
),
pr
om
in
en
t
ea
rs
(2
/3
),
th
in
lip
s
(2
/3
),
br
ac
hy
da
ct
yl
y
(2
/3
)
IF
T
81
2
2
2
3
C
ili
um
A
ss
em
bl
y
−
2.
9
±
0
−
3.
1
±
1
0/
3
w
id
e
na
sa
l
br
id
ge
(2
/2
),
hi
gh
ar
ch
ed
ey
e
br
ow
s
(2
/2
)
K
C
N
D
1
2
2
1
3
C
ar
di
ac
co
nd
uc
tio
n
−
2.
9
±
0.
4
−
2.
4
±
1.
1
0/
2
F
ai
r
ha
ir
(2
/2
),
sp
ar
se
ey
e
br
ow
s
(2
/2
),
th
in
lip
s
(2
/2
),
br
ac
hy
da
ct
yl
y
(2
/2
)
L
A
M
A
5
8b
4
4
4
3
H
um
an
pa
pi
llo
m
av
ir
us
in
fe
ct
io
n
−
2.
9
±
0.
6
−
1.
4
±
1.
1
2/
8
T
hi
n
lip
s
(4
/8
),
ba
rr
el
ch
es
t(
5/
8)
,s
an
da
lg
ap
(6
/8
)
M
E
D
24
2
1
1
5
4
T
hy
ro
id
ho
rm
on
e
si
gn
al
in
g
−
2.
5
±
0.
4
−
1.
5
±
0.
3
0/
2
T
hi
n
lip
s
(2
/2
),
br
ac
hy
da
ct
yl
y
(2
/2
)
P
L
X
N
A
3
2
2
5
3
A
xo
n
gu
id
an
ce
−
2
±
0.
3
−
0.
8
±
1
0/
2
L
at
er
al
hy
po
pl
as
ia
of
br
ow
s
(2
/2
),
br
oa
d
th
um
bs
(2
/2
)
R
A
S
A
3
2
1
1
4
3–
4
R
as
si
gn
al
in
g
−
2.
7
±
0.
5
−
2
±
0
0/
2
B
ro
ad
na
sa
l
tip
(2
/2
),
th
in
lip
s
(2
/2
),
ba
rr
el
ch
es
t
(2
/2
)
S
L
C
7A
8
2
2
3
3
P
ro
te
in
de
gr
ad
at
io
n
−
2.
9
±
0.
7
−
2
±
0.
5
0/
2
B
ra
ch
yd
ac
ty
ly
(2
/2
)
U
B
R
4
6b
5
1
4
2–
3
H
um
an
pa
pi
llo
m
av
ir
us
in
fe
ct
io
n
−
2.
9
±
0.
5
−
1
±
1.
2
3/
6
L
at
er
al
sp
ar
se
br
ow
s
(4
/6
),
ba
rr
el
ch
es
t
(4
/6
),
br
ac
hy
da
ct
yl
y
(5
/6
)
U
S
P
45
4
1
2
1
2
2–
4
D
N
A
R
ep
ai
r
−
2.
9
±
0.
7
−
1.
6
±
1.
1
0/
4
B
ra
ch
yd
ac
ty
ly
(4
/4
)
Z
F
H
X
3
2
1
1
5
3–
4
R
eg
ul
at
.
pl
ur
ip
ot
en
cy
of
st
em
ce
lls
−
2.
5
±
0.
7
−
2
±
0
0/
2
B
ra
ch
yd
ac
ty
ly
(2
/2
),
th
in
lip
s
(2
/2
),
ba
rr
el
ch
es
t
(2
/2
)
a S
eg
re
ga
tio
n
no
t
av
ai
la
bl
e
in
1
in
di
vi
du
al
b S
eg
re
ga
tio
n
no
t
av
ai
la
bl
e
in
4
in
di
vi
du
al
s
c m
ax
im
um
of
8
ge
ne
le
ve
l
ca
te
go
ri
es
d P
at
hw
ay
fr
om
K
E
G
G
/R
ea
ct
om
e
w
ith
th
e
hi
gh
es
t
fr
eq
ue
nc
y
of
se
le
ct
ed
ge
ne
s
w
ith
gr
ow
th
ph
en
ot
yp
e
(s
ee
al
so
S
up
pl
em
en
ta
ry
T
ab
le
10
e V
ar
ia
nt
le
ve
l
cl
as
si
ﬁ
ca
tio
n
(S
up
pl
em
en
ta
ry
T
ab
le
s
1-
4)
:
II
I—
V
ar
ia
nt
of
un
kn
ow
n
si
gn
iﬁ
ca
nc
e,
IV
—
lik
el
y
pa
th
og
en
ic
,
V
—
pa
th
og
en
ic
Evolutionary conserved networks of human height identify multiple Mendelian causes of short stature 1065
abundant variants were missense variants (78%), followed
by nonsense (15%), splice site (6%), and non-frameshift
insertion / deletion variants (1%). Nonsense variants were
identiﬁed in the high-conﬁdence candidate genes RASA3
and USP45. Based on in silico structural analysis, we
reclassiﬁed 5 variants in 4 of the high-conﬁdence candidate
genes from “variants of unknown signiﬁcance” (VUS) to
“likely pathogenic” (Fig. 1f and Supplementary Table 7).
Previously reported candidate genes
Of the 63 candidate genes we identiﬁed, 6 (9.5%) were
previously found to be associated with short stature or
syndromes featuring short stature (Table 3 and Supplemen-
tary Table 12). A de novo loss of the start codon in ZBED4
was found in another, smaller exome study in individuals
with ISS [14]. A missense variant in BRD4 was reported to
segregate in one family with short stature [20]. Variants in
FZD2 and LZTR1 were described in individuals with
Robinow syndrome-like phenotype (FZD2) [21, 22] and
Noonan syndrome (LZTR1), respectively [23, 24]. Recently,
variants in AMMECR1 were observed in individuals with
midface hypoplasia, hearing impairment, elliptocytosis, and
nephrocalcinosis (OMIM 300990) [25, 26]. Here, short
stature is a constant feature. Biallelic variants in IFT81
underlie a severe form of short stature (short-rib thoracic
dysplasia 19; OMIM 617895). Interestingly, a heterozygous
missense variant segregates with the growth deﬁcit in one
family, suggesting autosomal dominant inheritance.
Enrichment analysis and clustering of genes known
to be related to growth retardation
1025 genes potentially involved in growth delay or growth
regulation were selected using the keywords “growth delay”
from the Human Phenotype Ontology (HPO) database and
“short stature” from OMIM and MedGen (Supplementary
methods). Based on their signiﬁcantly enriched functions,
pathways and other biological features, we identiﬁed 29
clusters, including skeletal system development
(GO:0001501), appendage development (GO:0048736),
and ciliopathy and metabolic processes (GO:0044710)
(Fig. 1b). Moreover, clusters were often related to central
processes like chromatin binding (GO:0003682) or extra-
cellular matrix (GO:0310122).
Enrichment analysis revealed that 95% of the candidate
genes were mapped to 26 of the 29 clusters previously
implicated in growth or short stature (Fig. 1g and Table 4).
LAMA5 and MED24 were not mapped to any of these 29
clusters (Table 4 and Supplementary Tables 7, 10, and 11).
The main involved KEGG pathways for the 13 high-
conﬁdence candidate genes were: metabolic pathways
(hsa:01100), PI3K-Akt signaling pathway (hsa:04151), Ta
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signaling pathways regulating pluripotency of stem cells
(hsa:04550), thyroid hormone signaling pathway
(hsa:04919), and pathways in cancer (hsa:05200) (Table 2
and Supplementary Table 10).
Functional overview of 13 high-conﬁdence
candidate genes
Intensive review of the known function of the 13 high-
conﬁdence genes led to the localization in 7 functional
groups: Wnt signaling (CPZ, IFT81, LAMA5), cellular
growth regulation (EDEM3, KCND1, SLC7A8, UBR4),
thyroid hormone signaling (CPZ, KCND1, MED24), zeb-
raﬁsh phenotype (PLXNA3), Ras MAPK signaling
(RASA3), growth hormone signaling interaction (ZFHX3),
and ubiquitination (UBR4, USP45) (Supplementary
Table 9). 3 genes are known to be involved in Wnt reg-
ulation. CPZ is induced by thyroid hormones and modulates
Wnt signaling pathways by modiﬁcation of the activity of
Wnt-4 and thereby regulates the terminal differentiation of
growth plate chondrocytes. IFT81 encodes a member of the
IFT complex B core. Together with IFT74, IFT81 is
required for ciliogenesis. LAMA5 encodes the laminin
subunit alpha 5 and regulates Wnt- and PI3K signaling.
Besides CPZ, KCND1 and MED24 have a reported func-
tion in thyroid hormone signaling. KCND1 is expressed in
the thyroid gland which might imply a function in the
hormonal regulation of growth. MED24 encodes one of the
thyroid hormone receptor-associated proteins, that forms a
complex with the thyroid receptor via TRAP220 [27]. 5
high-conﬁdence genes, EDEM3, KCND1, SLC7A8, UBR4,
USP45, are involved in the regulation of cellular growth,
either by protein degradation (EDEM3), thyroid hormone
regulation (KCND1), the mTOR pathway (SLC7A8) or
ubiquitination (UBR4, USP45). Furthermore, ZFHX3
interacts with POU1F1, a member of the growth hormone
pathway. RASA3 encodes a Ras-GTPase activating protein
and is thus part of the RAS MAPK pathway.
Discussion
Growth-related disorders constitute a very heterogeneous
group of disorders. Based on the results from large GWAS
and gene-expression studies, we have estimated that at least
1000 genes are involved [5, 28]. These studies highlighted
the observation that rare, large effect-size variants of growth
retardation are inherited according to the three classical
patterns of Mendelian inheritance [28]. Nevertheless, 67%
of individuals with ISS remain without a diagnosis [5].
Using exome sequencing, we therefore aimed to identify
novel genes associated with short stature in 254 affected
families in whom known causes of short stature hadTa
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previously been excluded (Table 2, Supplementary Tables 7
and 11, and Supplementary Figure 1) [5]. We identiﬁed
variants in 63 candidate genes in a total of 92 independent
families. Based on a classiﬁcation scheme using variant and
gene information as well as the number of independent
affected individuals, we classiﬁed 13 genes as high-
conﬁdence genes and 50 other genes as medium-conﬁdence
candidates (Fig. 1c–e and Supplementary Figure 2).
To facilitate their characterization, we compiled a list of
1025 genes from HPO, OMIM, and MedGen based on the
keywords “growth delay” and “short stature” and clustered
their signiﬁcantly enriched functions, pathways and other
biological features. This resulted in 29 clusters, the largest
of which were skeletal system development, appendage
development, metabolic processes, and ciliopathy. These
clusters reﬂect not only processes of skeletal development
but also genes involved in basic processes like cellular
growth (Fig. 1a, b, Table 4, and Supplementary Figures 5–
7). Interestingly, the clusters with the highest mean
enrichment were bone morphogenesis (6.3-fold), peroxi-
some biogenesis disorder (6.0-fold), and ossiﬁcation (5.6-
fold). These results conﬁrmed a broad functional range of
potentially growth-related genes. In addition, we generated
a functional map of growth-associated genes that provides
general information on functions, pathways and other bio-
logical features overrepresented in this gene set. We were
able to map 95% of the 63 candidate genes onto at least one
of the 29 clusters, supporting their relevance to growth
(Fig. 1g and Table 4). These include the aforementioned
clusters with a high mean enrichment, but also more speciﬁc
clusters such as extracellular matrix, ossiﬁcation, bone
morphogenesis, and several catalytic processes.
The sensitivity of our approach to identify candidate
genes for short stature was further supported by the iden-
tiﬁcation of six genes (IFT81, AMMECR1, BRD4, FZD2,
LZTR1, ZBED4) recently found to be associated with this
phenotype (Table 3, Supplementary Table 12). Both the
previously reported mode of inheritance and the type of
variant were observed for AMMECR1 (X-linked recessive
loss of function variants) [25, 26], BRD4 (autosomal
dominant missense variants) [20] and ZBED4 (de novo
nonsense variants) [14]. In addition, the clinical phenotype
of the affected individuals was part of the phenotypic
spectrum reported, providing additional evidence for their
implication (Table 3 and Supplementary Table 12). Inter-
estingly, while nonsense variants in FZD2 cause severe
skeletal dysplasia phenotypes [21, 22], we identiﬁed mis-
sense variants in this gene in individuals with ISS, sug-
gesting that missense variants are associated with a milder
phenotype. IFT81 has previously been shown to be asso-
ciated with an autosomal recessive syndromic form of short
stature [24, 29, 30]. We propose that heterozygous variants
affecting only one allele cause only short stature, a
mechanism similar to that recently demonstrated for var-
iants in ACAN [9]. For LZTR1, which is involved in the
RAS-Map kinase pathway, the situation is more complex,
since variant type-dependent recessive and dominant
inheritance modes were observed to cause a Noonan-
spectrum disorder with short stature as a consistent phe-
notype [23, 24]. We hypothesize that speciﬁc missense
variants may be associated with isolated short stature.
RASA3 and FGF18 are two novel candidates implicated
in known signaling pathways. In RASA3, we identiﬁed a de
novo frameshift variant leading to a pre-terminal stop codon
in one individual, and a de novo missense variants located
in the C2 domain in a second individual, suggesting a loss-
of-function effect. Through collaboration, we identiﬁed one
additional individual with ISS and a de novo missense
variant in this domain. Molecular modeling revealed that
these missense variants potentially interfere with proper
function of the C2 domain, which is reported to be relevant
in targeting the protein to the cell membrane (Fig. 1f) [31].
Both the disruption of GTPase, mediated by a pre-terminal
stop codon, and mislocation in the cell may potentially
interfere with its proper function and thus lead to reduced
inactivation of Ras-signaling and further hyperactivation of
the pathway [32]. Likewise, FGF18 plays an important role
in chondrogenesis and osteogenesis by binding to FGFR2
and FGFR3 [33]. Gain-of-function variants in both recep-
tors were reported to cause mainly syndromic forms of short
stature [34–36]. We propose that, by analogy with other
members of this group of growth factors, a disease causing
variant in the interacting protein leads to constitutional
activation of the receptors in the complex [37].
Our classiﬁcation, in addition to variant and gene infor-
mation, is based on the number of independent affected
individuals. All 13 high-conﬁdence candidate genes were
identiﬁed in at least 2 families, and 5 candidates even
exhibited variants in up to 8 families. The most promising
candidates were LAMA5 with 4 variants likely affecting the
function and 4 variants of unknown signiﬁcance in 8
families, and UBR4 with 5 variants likely affecting the
function and 1 variant of unknown signiﬁcance in 6 families
(Table 2). All affected individuals carrying variants in either
of these genes presented with proportionate short stature
and a mean height that was 2.9 SDS below average. LAMA5
encodes the laminin subunit alpha 5, which plays a crucial
role in development by regulating Wnt and PI3K signaling
during osteoblast differentiation [38–40]. Recent reports
demonstrated an involvement in syndromes including kid-
ney disease, osteoarthritis and hypothyroidism, and an
association with reduced height in elderly individuals from
Southern Italy [41–44]. Studies in Lama5 mice with a
hypomorphic allele indicated an essential role for LAMA5 in
growth development [45]. Correspondingly, UBR4, the
ubiquitin protein ligase E3 component n-recognin 4, is
Evolutionary conserved networks of human height identify multiple Mendelian causes of short stature 1069
involved in cancer cell growth [46]. In Ubr4 knockout mice,
growth retardation was reported in fetuses [47]. A 3.46 Mb
deletion encompassing UBR4 was reported in an affected
individual with short stature [48]. Intolerance to missense
variants as indicated by a z-score of 5.98 (ExAC) suggested
that the variants identiﬁed in the 6 affected individuals are
highly likely to be associated with the phenotype [48, 49].
For another 50 genes, we found strong functional evidence
for their involvement, albeit some were identiﬁed only in a
single family. Thus, we cannot exclude that some genes may
be unrelated to short stature (Supplementary Table 8-10).
If we were to consider only the 13 high-conﬁdence
candidates, this would yield an exome sequencing detection
rate of 15% in highly selected families in whom known
causes were previously excluded. This probably constitutes
an underestimation as we assume that some of the other 50
candidate genes may be conﬁrmed in subsequent studies.
We may have missed smaller structural variants, variants in
noncoding or insufﬁciently covered regions, or epigenetic
changes, which have also been reported in connection with
short stature [4, 50]. Furthermore, polygenic inheritance,
mating selection and familial height variability may have
hampered the clinical characterization of, and hence the
identiﬁcation of, the underlying variant.
In conclusion, we identiﬁed and characterized 13 high-
conﬁdence candidate genes with variants in two or more
independent families and another 50 medium-conﬁdence
candidate genes. Of these candidate genes, 95% are anno-
tated with functions, pathways and other biological features
that are signiﬁcantly enriched among 1,025 growth-
associated genes. These results illustrate that in entities
with extremely high heterogeneity and complexity, such as
growth defects, clinical characterization and variant-level
and gene-level information need to be combined to identify
candidate genes. Our study also suggests that single gene
defects are an important contributor to the extreme lower
end of the growth distribution.
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